Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Revvity: Close To A Buy, Not Quite There
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
Here's Why Revvity (RVTY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
RVTY stock climbs after Q4 adjusted EPS of $1.70 top estimates with revenue improving 5.9% to $772.1 million.
Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates
Revvity (RVTY) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.42 per share a year ago.
Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery?
RVTY's Q4 results are likely to benefit from early demand recovery signs in Life Sciences, but China Diagnostics headwinds may limit earnings upside.
Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Revvity (RVTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
